Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease.
Ridruejo E, Mendizabal M, Silva MO.
Hemodial Int. 2018 Apr;22 Suppl 1:S97-S103. doi: 10.1111/hdi.12651.
Hepatitis C virus-related cryoglobulinemic vasculitis.
Mazzaro C, Mauro E, Ermacora A, Doretto P, Fumagalli S, Tonizzo M, Toffolutti F, Gattei V.
Minerva Med. 2021 Apr;112(2):175-187. doi: 10.23736/S0026-4806.20.07120-7. Epub 2020 Nov 16.
Hepatitis C.
Liddle C.
Anaesth Intensive Care. 1996 Apr;24(2):180-3. doi: 10.1177/0310057X9602400209.
Sofosbuvir-based hepatitis C therapies in patients with chronic and end-stage kidney disease.
Sise ME, McQuaid T, Martin P.
Nephrol Dial Transplant. 2022 Nov 23;37(12):2327-2334. doi: 10.1093/ndt/gfab072.
Is Moderate Alcohol Consumption Safe for Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women?
Lo Re V 3rd.
Clin Infect Dis. 2017 Nov 29;65(12):2057-2059. doi: 10.1093/cid/cix720.
Chronic hepatitis C genotype 1 virus: who should wait for treatment?
Tovo CV, de Mattos AA, de Almeida PR.
World J Gastroenterol. 2014 Mar 21;20(11):2867-75. doi: 10.3748/wjg.v20.i11.2867.
Increased Mortality Among Persons With Chronic Hepatitis C With Moderate or Severe Liver Disease: A Cohort Study.
Cepeda JA, Thomas DL, Astemborski J, Sulkowski MS, Kirk GD, Mehta SH.
Clin Infect Dis. 2017 Jul 15;65(2):235-243. doi: 10.1093/cid/cix207.
Daclatasvir for the treatment of chronic hepatitis C.
Degasperi E, Aghemo A, Colombo M.
Expert Opin Pharmacother. 2015;16(17):2679-88. doi: 10.1517/14656566.2015.1109631. Epub 2015 Nov 7.
Current therapy for chronic hepatitis C: The role of direct-acting antivirals.
Li G, De Clercq E.
Antiviral Res. 2017 Jun;142:83-122. doi: 10.1016/j.antiviral.2017.02.014. Epub 2017 Feb 24.
Co-infections, comorbidities, and alcohol or other substances abuses in chronic hepatitis C-related hospitalisations in Spain.
Garrido-Estepa M, Herruzo R, Flores-Herrera J.
Gastroenterol Hepatol. 2022 Nov;45(9):677-689. doi: 10.1016/j.gastrohep.2022.01.002. Epub 2022 Jan 19.
